Core Viewpoint - The FDA is taking decisive steps to restrict the use of GLP-1 active pharmaceutical ingredients in non-approved drugs [1] Group 1 - The FDA's actions indicate a regulatory tightening around GLP-1 drugs, which may impact companies involved in the development and marketing of these pharmaceuticals [1]

Core Point - The U.S. Food and Drug Administration has issued a warning letter to telehealth firm Hims & Hers Health concerning its compounded versions of Novo Nordisk's diabetes drug Ozempic and weight-loss treatment Wegovy [1] Company Summary - Hims & Hers Health is facing regulatory scrutiny from the FDA for its compounded medications related to popular diabetes and weight-loss treatments [1] Industry Summary - The telehealth industry is experiencing increased regulatory oversight, particularly regarding the compounding of pharmaceuticals, which may impact operational practices and compliance requirements [1]